Aproximación práctica a la insulinoterapia

La diabetes mellitus tipo 2 (DM 2) es una patología de alta prevalencia y gran repercusión a nivel de salud pública, la cual se está diagnosticando tardíamente en su historia natural. Actualmente, se está dando mayor relevancia a la disfunción de la célula beta desde el comienzo de la enfermedad sin...

Full description

Autores:: Restrepo Vesga, Paola
Sandoval Sus, José David

Tipo de recurso:: Article of journal

Fecha de publicación:: 2006

Institución:: Universidad Autónoma de Bucaramanga - UNAB

Repositorio:: Repositorio UNAB

Idioma:: spa

id	UNAB2_67bdfb0dac3a0016f003af0ad5e19c15
oai_identifier_str	oai:repository.unab.edu.co:20.500.12749/10403
network_acronym_str	UNAB2
network_name_str	Repositorio UNAB
repository_id_str
dc.title.none.fl_str_mv	Aproximación práctica a la insulinoterapia
dc.title.translated.eng.fl_str_mv	A practical approach to insulin therapy
title	Aproximación práctica a la insulinoterapia
spellingShingle	Aproximación práctica a la insulinoterapia Ciencias de la salud Ciencias biomédicas Ciencias de la vida Innovaciones en salud Investigaciones Health Sciences Medicine Medical Sciences Biomedical Sciences Life Sciences Innovations in health Research Diabetes mellitus type 2 Insuline Insulinotherapy Ciencias médicas Medicina Diabetes Mellitus tipo 2 Insulina Insulinoterapia
title_short	Aproximación práctica a la insulinoterapia
title_full	Aproximación práctica a la insulinoterapia
title_fullStr	Aproximación práctica a la insulinoterapia
title_full_unstemmed	Aproximación práctica a la insulinoterapia
title_sort	Aproximación práctica a la insulinoterapia
dc.creator.fl_str_mv	Restrepo Vesga, Paola Sandoval Sus, José David
dc.contributor.author.spa.fl_str_mv	Restrepo Vesga, Paola Sandoval Sus, José David
dc.subject.none.fl_str_mv	Ciencias de la salud Ciencias biomédicas Ciencias de la vida Innovaciones en salud Investigaciones
topic	Ciencias de la salud Ciencias biomédicas Ciencias de la vida Innovaciones en salud Investigaciones Health Sciences Medicine Medical Sciences Biomedical Sciences Life Sciences Innovations in health Research Diabetes mellitus type 2 Insuline Insulinotherapy Ciencias médicas Medicina Diabetes Mellitus tipo 2 Insulina Insulinoterapia
dc.subject.keywords.eng.fl_str_mv	Health Sciences Medicine Medical Sciences Biomedical Sciences Life Sciences Innovations in health Research
dc.subject.keywords.none.fl_str_mv	Diabetes mellitus type 2 Insuline Insulinotherapy
dc.subject.lemb.none.fl_str_mv	Ciencias médicas Medicina
dc.subject.proposal.none.fl_str_mv	Diabetes Mellitus tipo 2 Insulina Insulinoterapia
description	La diabetes mellitus tipo 2 (DM 2) es una patología de alta prevalencia y gran repercusión a nivel de salud pública, la cual se está diagnosticando tardíamente en su historia natural. Actualmente, se está dando mayor relevancia a la disfunción de la célula beta desde el comienzo de la enfermedad sin dejar de lado la ya conocida resistencia periférica a la insulina. La falla progresiva de estas células pancreáticas lleva a un mal control de los niveles glucémicos con inicio temprano de la insulinoterapia. En el presente artículo se expone de una forma sencilla el papel de la insulinoterapia en la DM2 las indicaciones, métodos de dosificación insulínica, efectos adversos y metas deseadas de control en el paciente diabético.[Restrepo P, Sandoval JD. Aproximación práctica a la insulinoterapia. MedUNAB 2006;9:51-57]
publishDate	2006
dc.date.issued.none.fl_str_mv	2006-04-02
dc.date.accessioned.none.fl_str_mv	2020-10-27T14:21:35Z
dc.date.available.none.fl_str_mv	2020-10-27T14:21:35Z
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.spa.fl_str_mv	Artículo
dc.type.coar.none.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.redcol.none.fl_str_mv	http://purl.org/redcol/resource_type/ART
format	http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv	2382-4603 0123-7047
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/20.500.12749/10403
dc.identifier.instname.spa.fl_str_mv	instname:Universidad Autónoma de Bucaramanga UNAB
dc.identifier.repourl.none.fl_str_mv	repourl:https://repository.unab.edu.co
identifier_str_mv	2382-4603 0123-7047 instname:Universidad Autónoma de Bucaramanga UNAB repourl:https://repository.unab.edu.co
url	http://hdl.handle.net/20.500.12749/10403
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.none.fl_str_mv	https://revistas.unab.edu.co/index.php/medunab/article/view/168/153
dc.relation.uri.none.fl_str_mv	https://revistas.unab.edu.co/index.php/medunab/article/view/168
dc.relation.references.none.fl_str_mv	Aschner P, et al. Guías ALAD 2000 para el diagnostico y manejo de la diabetes mellitus tipo 2 con medicina basada en el evidencia. Rev Asoc Latinoam Diab 2000; Supl. 1 Ed. Extraordinaria Leahy J. What is the role for insulin therapy in type 2 diabetes? Curr Op Endocrinol Diabetes 2003; 10:99 -103 Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4 -7 yrs before clinical diagnosis. Diabetes care 1992; 15: 815 – 9 Harris MI, Flegal KM, Cowie CC, Eberhardt MS et al. Preva-lence of diabetes, impaired fasting glucose and impair glucose tolerance in U.S. adults: the Third National Health and Nutrition examination Survey 1988 -1994. Diabetes care 1998; 21: 518 – 24 White J, et al. clarifying the role of insulin in type 2 diabetes management. Clinical diabetes 2003; 21: 14 -21 U.K. Prospective Study Group: Intensive blood – glucose control with sulphonylureas or insulin compared with conventional treat-ment and risk of complications in patients with type 2 diabetes. Lancet 1998; 353: 837 – 53 Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes care 2004; 27: 17 -20 Mayfield J, White R. Insulin theraoy for type 2 diabetes: Rescue, augmentation, and replacement of beta cell function. Am Fam Physician 2004; 70:489 – 500 Kahn SE. The importance of the beta –cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108(Suppl 6a): 2S -8 Glaser B, Cerasi E. Early intensive insulin treatment for induction of long –term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999; 1: 67 -74 Polosky KS, Given BD, Hirsch LJ, Tillil H, et al. Abnormal pat-terns of insulin secretion in non – insulin – dependent diabetes mellitus. N Eng J Med 1988; 318: 1231 - 9 Defronzo RA. Pharmacologic therapy for type 2 diabetes. Ann Intern Med 1999; 131: 281 – 303 Levobitz HE. Oral therapies for diabetic hyperglycemia. Endo-crinol Metab Clin North Am 2001; 30: 909 – 33 Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazo-lidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes poorly control with sulfonylurea and metformina. A multicenter, randomized, double – blind, placebo controlled trial. Ann Inter Med 2001, 134: 737 – 45 Hirsch IR, et al. A real world approach to insulin therapy in primary care practice. Clinical diabetes 2005, 23: 78 – 86 The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long – term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977 – 86 Ohkubo Y, et al. Intensive insulin therapy prevents the pro-gression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103 – 17 Gaede P, et al. Multifactorial intervention and cardiovascular diseases in patients with type 2 diabetes. N Eng J Med 2003; 348: 338 -93 Vehkavaara S, et al. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 545 -50 Rosenfeld L. Insulin: discovery and controversy. Clin Chem 2002; 48: 2270 -88 Hirsch IR. Insulin Analogues. N Eng J Med. 2005; 352: 174 -83 DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA. 2003; 289: 2254 -64 Ward Wk, Bolngiano DC, McKnigth B, Halter JB, Porte D Jr. Diminish B-cell secretory capacity in patients in patients with non – insulin diabetes mellitus. J Clin Invest. 1984; 74: 1318-28 Holleman F. Insulin lispro. N Eng J Med. 1997; 337: 176 – Freemantke N, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes care. 2005; 28: 427 -28 Lepore M, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection long-acting human insulin analogue glargine, NPH insulin and ultralente human insulin and conti-nuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49: 2142 -8 Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. Lyspro human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994; 43: 396 – 402 Riddle M, Rosenstock J, Gerich J. The Treat To Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes care. 2003; 26: 3080 -6 DeFronzo RA, ed. Current therapy of diabetes mellitus. St.Louis: Mosby, 1998: 108-16 Bastyr EJ 3d, et al. Therapy focus on lowering postprandial glu-cose, not fasting glucose, may be superior for lowering HbA1c. Diabetes care. 2000; 23: 1236 -41 Hope PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter double – blind crossover trial in type 1 diabetic patients. Diabetes care 1998; 21: 1904 -9 Bastyr EJ 3d, et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther. 1999; 21: 1703 -14 Haffner SM, et al. Insulin sensitivity in type 2 diabetic patients: relationship with cardiovascular risk factors: the insulin resis-tance atherosclerosis study. Diabetes care. 1999; 562-8 Raskin P, Rojas P, Allen E. Comparison of twice-daily biphasic insulin apart 70/30 (BIAsp 70/30) with once daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabteic agents. Diabetes. 2004 (Suppl 2); 602-P Perseghin G, et al. Increase glucose transport – phosphorylation and muscle glycogen synthesis after exercise training insulin – resistance subjects. N Eng J Med. 1996; 335: 1357 – 62 Yki-Jarvinein H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001; 24: 758 – 67 Yki-Jarvinein H, et al. Comparison of bed time insulin regimens in patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Inter Med. 1999; 130: 389- 96 American Diabetes Association. Standards of medical care for patients with Diabetes Mellitus (Position statement). Diabetes Care. 2005; (Suppl. 1): S4 – 36
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/
rights_invalid_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Universidad Autónoma de Bucaramanga UNAB
dc.publisher.faculty.none.fl_str_mv	Facultad Ciencias de la Salud
dc.publisher.program.none.fl_str_mv	Pregrado Medicina
publisher.none.fl_str_mv	Universidad Autónoma de Bucaramanga UNAB
dc.source.none.fl_str_mv	MedUNAB; Vol. 9 Núm. 1 (2006): Linfocitos B, Mortalidad Evitable, Trastornos del sueño; 51-57
institution	Universidad Autónoma de Bucaramanga - UNAB
bitstream.url.fl_str_mv	https://repository.unab.edu.co/bitstream/20.500.12749/10403/1/2006_Aproximaci%c3%b3n_pr%c3%a1ctica_a_la_insulinoterapia.pdf https://repository.unab.edu.co/bitstream/20.500.12749/10403/2/2006_Aproximaci%c3%b3n_pr%c3%a1ctica_a_la_insulinoterapia.pdf.jpg
bitstream.checksum.fl_str_mv	aaa6490c10fb699fcfe567ac9b509410 e6f8a7e342ac0b2eb48188495227c0c7
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional \| Universidad Autónoma de Bucaramanga - UNAB
repository.mail.fl_str_mv	repositorio@unab.edu.co
_version_	1814277902808645632
spelling	Restrepo Vesga, Paolabbc16888-cabc-4460-9ed2-1d9b1203b8dc-1Sandoval Sus, José Davida4c5a411-b882-4c0f-967e-bf847933e9d9-12020-10-27T14:21:35Z2020-10-27T14:21:35Z2006-04-022382-46030123-7047http://hdl.handle.net/20.500.12749/10403instname:Universidad Autónoma de Bucaramanga UNABrepourl:https://repository.unab.edu.coLa diabetes mellitus tipo 2 (DM 2) es una patología de alta prevalencia y gran repercusión a nivel de salud pública, la cual se está diagnosticando tardíamente en su historia natural. Actualmente, se está dando mayor relevancia a la disfunción de la célula beta desde el comienzo de la enfermedad sin dejar de lado la ya conocida resistencia periférica a la insulina. La falla progresiva de estas células pancreáticas lleva a un mal control de los niveles glucémicos con inicio temprano de la insulinoterapia. En el presente artículo se expone de una forma sencilla el papel de la insulinoterapia en la DM2 las indicaciones, métodos de dosificación insulínica, efectos adversos y metas deseadas de control en el paciente diabético.[Restrepo P, Sandoval JD. Aproximación práctica a la insulinoterapia. MedUNAB 2006;9:51-57]Diabetes mellitus type 2 (DM 2) is patology of high prevalence and great repercusion in public health, and it ́s been diagnosed late in the natural histoty of the disease. At the moment, it is been given greater relevance to the disfunction of beta cells since the begining of the disease without leaving apart the periferic insulin resistance that is already known. The progresive failure of these pancreatic cells leads to a poor glicemic control with an early use of inslin therapy. In these article it ́s presented in a simple way the function of insulin therapy in DM 2, indications, insulin dosification metods, adverse effects and wished goals for glicemic control in diabetic patients. [Restrepo P, Sandoval JS.Practical approach to insulinotherapy. MedUNAB 2006; 9:51-57application/pdfspaUniversidad Autónoma de Bucaramanga UNABFacultad Ciencias de la SaludPregrado Medicinahttps://revistas.unab.edu.co/index.php/medunab/article/view/168/153https://revistas.unab.edu.co/index.php/medunab/article/view/168Aschner P, et al. Guías ALAD 2000 para el diagnostico y manejo de la diabetes mellitus tipo 2 con medicina basada en el evidencia. Rev Asoc Latinoam Diab 2000; Supl. 1 Ed. ExtraordinariaLeahy J. What is the role for insulin therapy in type 2 diabetes? Curr Op Endocrinol Diabetes 2003; 10:99 -103Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4 -7 yrs before clinical diagnosis. Diabetes care 1992; 15: 815 – 9Harris MI, Flegal KM, Cowie CC, Eberhardt MS et al. Preva-lence of diabetes, impaired fasting glucose and impair glucose tolerance in U.S. adults: the Third National Health and Nutrition examination Survey 1988 -1994. Diabetes care 1998; 21: 518 – 24White J, et al. clarifying the role of insulin in type 2 diabetes management. Clinical diabetes 2003; 21: 14 -21U.K. Prospective Study Group: Intensive blood – glucose control with sulphonylureas or insulin compared with conventional treat-ment and risk of complications in patients with type 2 diabetes. Lancet 1998; 353: 837 – 53Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes care 2004; 27: 17 -20Mayfield J, White R. Insulin theraoy for type 2 diabetes: Rescue, augmentation, and replacement of beta cell function. Am Fam Physician 2004; 70:489 – 500Kahn SE. The importance of the beta –cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108(Suppl 6a): 2S -8Glaser B, Cerasi E. Early intensive insulin treatment for induction of long –term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999; 1: 67 -74Polosky KS, Given BD, Hirsch LJ, Tillil H, et al. Abnormal pat-terns of insulin secretion in non – insulin – dependent diabetes mellitus. N Eng J Med 1988; 318: 1231 - 9Defronzo RA. Pharmacologic therapy for type 2 diabetes. Ann Intern Med 1999; 131: 281 – 303Levobitz HE. Oral therapies for diabetic hyperglycemia. Endo-crinol Metab Clin North Am 2001; 30: 909 – 33Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazo-lidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes poorly control with sulfonylurea and metformina. A multicenter, randomized, double – blind, placebo controlled trial. Ann Inter Med 2001, 134: 737 – 45Hirsch IR, et al. A real world approach to insulin therapy in primary care practice. Clinical diabetes 2005, 23: 78 – 86The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long – term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977 – 86Ohkubo Y, et al. Intensive insulin therapy prevents the pro-gression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103 – 17Gaede P, et al. Multifactorial intervention and cardiovascular diseases in patients with type 2 diabetes. N Eng J Med 2003; 348: 338 -93Vehkavaara S, et al. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 545 -50Rosenfeld L. Insulin: discovery and controversy. Clin Chem 2002; 48: 2270 -88Hirsch IR. Insulin Analogues. N Eng J Med. 2005; 352: 174 -83DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA. 2003; 289: 2254 -64Ward Wk, Bolngiano DC, McKnigth B, Halter JB, Porte D Jr. Diminish B-cell secretory capacity in patients in patients with non – insulin diabetes mellitus. J Clin Invest. 1984; 74: 1318-28Holleman F. Insulin lispro. N Eng J Med. 1997; 337: 176 –Freemantke N, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes care. 2005; 28: 427 -28Lepore M, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection long-acting human insulin analogue glargine, NPH insulin and ultralente human insulin and conti-nuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49: 2142 -8Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. Lyspro human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994; 43: 396 – 402Riddle M, Rosenstock J, Gerich J. The Treat To Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes care. 2003; 26: 3080 -6DeFronzo RA, ed. Current therapy of diabetes mellitus. St.Louis: Mosby, 1998: 108-16Bastyr EJ 3d, et al. Therapy focus on lowering postprandial glu-cose, not fasting glucose, may be superior for lowering HbA1c. Diabetes care. 2000; 23: 1236 -41Hope PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter double – blind crossover trial in type 1 diabetic patients. Diabetes care 1998; 21: 1904 -9Bastyr EJ 3d, et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther. 1999; 21: 1703 -14Haffner SM, et al. Insulin sensitivity in type 2 diabetic patients: relationship with cardiovascular risk factors: the insulin resis-tance atherosclerosis study. Diabetes care. 1999; 562-8Raskin P, Rojas P, Allen E. Comparison of twice-daily biphasic insulin apart 70/30 (BIAsp 70/30) with once daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabteic agents. Diabetes. 2004 (Suppl 2); 602-PPerseghin G, et al. Increase glucose transport – phosphorylation and muscle glycogen synthesis after exercise training insulin – resistance subjects. N Eng J Med. 1996; 335: 1357 – 62Yki-Jarvinein H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001; 24: 758 – 67Yki-Jarvinein H, et al. Comparison of bed time insulin regimens in patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Inter Med. 1999; 130: 389- 96American Diabetes Association. Standards of medical care for patients with Diabetes Mellitus (Position statement). Diabetes Care. 2005; (Suppl. 1): S4 – 36http://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2MedUNAB; Vol. 9 Núm. 1 (2006): Linfocitos B, Mortalidad Evitable, Trastornos del sueño; 51-57Ciencias de la saludCiencias biomédicasCiencias de la vidaInnovaciones en saludInvestigacionesHealth SciencesMedicineMedical SciencesBiomedical SciencesLife SciencesInnovations in healthResearchDiabetes mellitus type 2InsulineInsulinotherapyCiencias médicasMedicinaDiabetes Mellitus tipo 2InsulinaInsulinoterapiaAproximación práctica a la insulinoterapiaA practical approach to insulin therapyinfo:eu-repo/semantics/articleArtículohttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/redcol/resource_type/ARTORIGINAL2006_Aproximación_práctica_a_la_insulinoterapia.pdf2006_Aproximación_práctica_a_la_insulinoterapia.pdfArticuloapplication/pdf1151961https://repository.unab.edu.co/bitstream/20.500.12749/10403/1/2006_Aproximaci%c3%b3n_pr%c3%a1ctica_a_la_insulinoterapia.pdfaaa6490c10fb699fcfe567ac9b509410MD51open accessTHUMBNAIL2006_Aproximación_práctica_a_la_insulinoterapia.pdf.jpg2006_Aproximación_práctica_a_la_insulinoterapia.pdf.jpgIM Thumbnailimage/jpeg7090https://repository.unab.edu.co/bitstream/20.500.12749/10403/2/2006_Aproximaci%c3%b3n_pr%c3%a1ctica_a_la_insulinoterapia.pdf.jpge6f8a7e342ac0b2eb48188495227c0c7MD52open access20.500.12749/10403oai:repository.unab.edu.co:20.500.12749/104032024-04-15 16:28:48.911open accessRepositorio Institucional \| Universidad Autónoma de Bucaramanga - UNABrepositorio@unab.edu.co

Aproximación práctica a la insulinoterapia

Publicaciones similares